Cargando…

Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors

OBJECTIVE: We aimed to evaluate whether the systemic inflammatory response index (SIRI) and platelet lymphocyte ratio (PLR) are associated with ovarian malignancy and their diagnostic value. Design: This retrospective study compared SIRI, PLR, cancer antigen 125 (CA125), cancer antigen 153 (CA153),...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huifang, Wu, Kunhai, Chen, Lufei, Lin, Xiaomei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694276/
https://www.ncbi.nlm.nih.gov/pubmed/34955651
http://dx.doi.org/10.2147/IJGM.S346610
_version_ 1784619318060777472
author Huang, Huifang
Wu, Kunhai
Chen, Lufei
Lin, Xiaomei
author_facet Huang, Huifang
Wu, Kunhai
Chen, Lufei
Lin, Xiaomei
author_sort Huang, Huifang
collection PubMed
description OBJECTIVE: We aimed to evaluate whether the systemic inflammatory response index (SIRI) and platelet lymphocyte ratio (PLR) are associated with ovarian malignancy and their diagnostic value. Design: This retrospective study compared SIRI, PLR, cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 199 (CA199), A carcinoma embryonic antigen (CEA) and alpha fetal protein (AFP) of the two groups in Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University from January 2018 to December 2020, divided into two groups based on pathological results, including 85 with ovarian malignancy who met the study criteria and 85 patients with benign ovarian tumors were randomly selected as control group. RESULTS: 1) SIRI and PLR in benign ovarian tumor group were lower than those in ovarian malignancy group; 2) SIRI and PLR in ovarian malignant tumor low stage group were lower than those in the high stage group; 3) In ovarian malignancies, SIRI and PLR were positively associated with CA125 (the correlation coefficient r = 0.251, p = 0.021; r = 0.251, p = 0.020;) but showed no correlation with CA153. CONCLUSION: The study shows that SIRI and PLR are both convenient and associated with ovarian malignancy. SIRI and PLR can be used to help the differentiation of benign and malignant ovarian tumors and can also be used in the markers of ovarian malignant tumors roughly staging.
format Online
Article
Text
id pubmed-8694276
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-86942762021-12-23 Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors Huang, Huifang Wu, Kunhai Chen, Lufei Lin, Xiaomei Int J Gen Med Original Research OBJECTIVE: We aimed to evaluate whether the systemic inflammatory response index (SIRI) and platelet lymphocyte ratio (PLR) are associated with ovarian malignancy and their diagnostic value. Design: This retrospective study compared SIRI, PLR, cancer antigen 125 (CA125), cancer antigen 153 (CA153), cancer antigen 199 (CA199), A carcinoma embryonic antigen (CEA) and alpha fetal protein (AFP) of the two groups in Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University from January 2018 to December 2020, divided into two groups based on pathological results, including 85 with ovarian malignancy who met the study criteria and 85 patients with benign ovarian tumors were randomly selected as control group. RESULTS: 1) SIRI and PLR in benign ovarian tumor group were lower than those in ovarian malignancy group; 2) SIRI and PLR in ovarian malignant tumor low stage group were lower than those in the high stage group; 3) In ovarian malignancies, SIRI and PLR were positively associated with CA125 (the correlation coefficient r = 0.251, p = 0.021; r = 0.251, p = 0.020;) but showed no correlation with CA153. CONCLUSION: The study shows that SIRI and PLR are both convenient and associated with ovarian malignancy. SIRI and PLR can be used to help the differentiation of benign and malignant ovarian tumors and can also be used in the markers of ovarian malignant tumors roughly staging. Dove 2021-12-18 /pmc/articles/PMC8694276/ /pubmed/34955651 http://dx.doi.org/10.2147/IJGM.S346610 Text en © 2021 Huang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Huang, Huifang
Wu, Kunhai
Chen, Lufei
Lin, Xiaomei
Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title_full Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title_fullStr Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title_full_unstemmed Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title_short Study on the Application of Systemic Inflammation Response Index and Platelet–Lymphocyte Ratio in Ovarian Malignant Tumors
title_sort study on the application of systemic inflammation response index and platelet–lymphocyte ratio in ovarian malignant tumors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694276/
https://www.ncbi.nlm.nih.gov/pubmed/34955651
http://dx.doi.org/10.2147/IJGM.S346610
work_keys_str_mv AT huanghuifang studyontheapplicationofsystemicinflammationresponseindexandplateletlymphocyteratioinovarianmalignanttumors
AT wukunhai studyontheapplicationofsystemicinflammationresponseindexandplateletlymphocyteratioinovarianmalignanttumors
AT chenlufei studyontheapplicationofsystemicinflammationresponseindexandplateletlymphocyteratioinovarianmalignanttumors
AT linxiaomei studyontheapplicationofsystemicinflammationresponseindexandplateletlymphocyteratioinovarianmalignanttumors